Viridian Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Viridian Therapeutics, Inc. (VRDN) holds an ST Score of 59.8 out of 100 (B-), with its strongest factor being Forecast (A) and its weakest Profitability (C+). Analysts rate VRDN Buy across 16 ratings with a $36.14 average price target (+0.6% vs the current $22.00).
- Strongest
- ForecastA
- Weakest
- ProfitabilityC+
All factor grades
- ForecastA
- ValuationB
- Financial StrengthB
- GrowthB
- MomentumB-
- ProfitabilityC+
- Piotroski3/9
Contact
VRDN stock: frequently asked questions
What is VRDN's ST Score?
Viridian Therapeutics, Inc. (VRDN) has an ST Score of 59.8 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is VRDN a buy, sell, or hold?
Wall Street's consensus rating on VRDN is Buy based on 16 analyst ratings. Our own ST Score grades it B- (59.8/100). This is data, not investment advice — always do your own research.
What is VRDN's valuation grade?
Viridian Therapeutics, Inc. (VRDN) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is VRDN's growth grade?
Viridian Therapeutics, Inc. (VRDN) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is VRDN's profitability grade?
Viridian Therapeutics, Inc. (VRDN) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is VRDN's financial strength grade?
Viridian Therapeutics, Inc. (VRDN) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for VRDN?
The average analyst price target for Viridian Therapeutics, Inc. (VRDN) is $36.14 from 16 analysts, which is +0.6% versus the recent price of $22.00.
What is VRDN's Piotroski score?
Viridian Therapeutics, Inc. (VRDN) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.